ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.Journal of neurology · 2022Trial
- A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.Neurology and therapy · 2026Article
- COVID-19 and Radiological Progression of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2026Article
- Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.Therapeutic advances in neurological disorders · 2026Article
- Effectiveness of disease management across healthcare settings: the Multiple Sclerosis Center is a pillar for multi-disciplinary practices that promote quality of life for people with Multiple Sclerosis.Frontiers in public health · 2026Article
- SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.Journal of neurology · 2025Article
- Patient Perspectives on Healthcare Utilization During the COVID-19 Pandemic in People with Multiple Sclerosis-A Longitudinal Analysis.Healthcare (Basel, Switzerland) · 2025Article
- The impact of COVID-19 pandemic on patients with Huntington's disease and care-givers: A French survey.eNeurologicalSci · 2024Article
- ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation.PharmacoEconomics - open · 2024Article
- Era of COVID-19 in Multiple Sclerosis Care.Neurologic clinics · 2024Review
- Psychosocial Effects of the Pandemic on MS Patients at a University Hospital Following Patients with Telemedicine, Cross-sectional Study.Noro psikiyatri arsivi · 2023Article
- Screening for Cystic Fibrosis Related Complications in the Context of a Pandemic and Altered Models of Care.Health services insights · 2023Article
- Social support predicts sleep quality in people with multiple sclerosis during the COVID-19 pandemic.Multiple sclerosis and related disorders · 2022Article
- Healthcare Disruptions and Use of Telehealth Services Among People With Multiple Sclerosis During the COVID-19 Pandemic.Archives of physical medicine and rehabilitation · 2022Article
- Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach.Neurology international · 2022Review
- The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.Journal of neurology · 2022Article
- Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.Journal of neurology · 2022Article
- Adherence to Therapy in Patients with Multiple Sclerosis-Review.International journal of environmental research and public health · 2022Review
- Lessons learned from people with neurological diseases at the time of COVID-19: The EFNA-EAN survey.European journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS).
objectivesTo collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices.
methodsBetween March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19.
resultsThree-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment.
conclusionThe ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.